Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
about
Low-dose rate brachytherapy for men with localized prostate cancerComparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost.Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma.Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer.Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis.Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer.Predictors in the outcome of 125I brachytherapy as monotherapy for prostate cancer.Interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer.Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective.Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapyMinimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer.PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up.Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.Rapid Increase of the Serum PSA Level in Response to High-Intensity Focused Ultrasound Therapy may be a Potential Indicator of Biochemical Recurrence of Low- and Intermediate-Risk Prostate Cancer.Biochemical control of prostate cancer with iodine-125 brachytherapy alone: experience from a single institution.Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.125I brachytherapy in younger prostate cancer patients : Outcomes in low- and intermediate-risk disease.Outcomes after prostate brachytherapy are even better than predicted.Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer.Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma.Prostate specific antigen bounce after intensity-modulated radiation therapy in an Asian population.Surrogate endpoints in early prostate cancer researchLow-dose-rate brachytherapy as a minimally invasive curative treatment for localised prostate cancer has excellent oncological and functional outcomes: a retrospective analysis from a single centre
P2860
Q24235544-C6011788-DF31-4CB5-9CB3-A2ECF58D6FE9Q34008499-2F1E2319-73BD-454C-93D9-F14D5705BECDQ35024651-30695A24-CF6D-4D3A-A110-2B3F4AEFD1DFQ35649108-BF21CFB1-5438-406F-86DC-65A4FD8E22E4Q35797101-89E8326E-2682-40B3-AF92-99B5C8DF1D54Q35917240-247CD0D5-176B-4765-A687-70564BFD4B0CQ37506972-B2CBF026-B10E-48A4-8F2B-B96C5FBD34B7Q37522643-E93AF1C9-05AA-41BF-A934-7A7FE87DA4E3Q37821905-02693FE0-50A4-47A9-B81D-37575B3F85C4Q38035932-1BA7512B-916E-4B7B-B07B-9B2F90A3DB57Q38539324-FC7BC14F-BF56-4891-914A-51162EAC2E34Q39610086-B5A40052-FAB9-4654-9057-BA89C9EC4810Q41525303-84C2B745-F769-4BEB-B76B-5633B3E44F3FQ41545981-485A6836-3DDC-457A-AF55-4D387DF5E72EQ41833600-7BCB15EF-98D4-406C-90AA-40A4C26E4FF4Q42734238-A3FC7DAD-CAD4-4BF7-9A88-4133C40E9EB7Q44805211-9595E5FB-A436-46F6-BED5-ACE41EC1B0D8Q48902630-6111FF6C-DBB8-4A3A-A863-594A6F7E0602Q51011445-29124DB3-6B03-4485-8100-FC6EA71F99A5Q51021374-DD7D725D-988D-442F-9CA6-A5D317F43CEBQ52606123-7D3D9663-75A3-4B63-97C4-D3D534692109Q54177637-17D9B7F2-620F-4506-9A89-55A8DE82C07DQ55401646-DAEDBC59-2588-490F-9CED-0CDC5B9BCCF7Q57112339-E8112292-3604-4427-9B99-8650073DDB56Q58578875-DA35A8F9-D4B9-4FE7-8432-F374883AECCD
P2860
Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Prostate-specific antigen boun ...... descriptions and implications.
@en
type
label
Prostate-specific antigen boun ...... descriptions and implications.
@en
prefLabel
Prostate-specific antigen boun ...... descriptions and implications.
@en
P2093
P1476
Prostate-specific antigen boun ...... descriptions and implications.
@en
P2093
Jamie A Cesaretti
Nelson N Stone
Richard G Stock
P304
P356
10.1016/S0360-3016(02)04470-X
P407
P577
2003-06-01T00:00:00Z